Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Contemporary Management of HIV 2021: Emerging Paradigms in ART

Listen as expert faculty consider important clinical questions related to rapid ART initiation, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies in the treatment of HIV.
Paul E. Sax, MD
Released: August 25, 2021

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:

  • The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period
  • The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosis
  • A rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse events
  • The ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPV
  • SWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effective
  • GEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDF
  • TANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimen

In addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.

Information on this Educational Activity


Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has served as a consultant or on a scientific advisory board for Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and that he has received funds for research support from Gilead Sciences, GlaxoSmithKline/ViiV, and Merck.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Breve vlog de la Dra. Alicia Piñeirúa Menéndez sobre la optimización del TAR en un paciente con VIH y tuberculosis activa en México de Clinical Care Options (CCO)

person default Alicia Piñeirúa Menéndez, MD, MPH Released: May 20, 2022

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Paul E. Sax, MD
Released: May 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings